* If you want to update the article please login/register
The aim of this study was to find out if IL13 gene polymorphism and serum periostin levels among Egyptian patients with asthma and AC. Results: ELISA discovered that asthmatic patients had a higher prevalence of the homozygous adenine genotype at IL13 rs20541 SNP and a lower incidence of the apoptic adenine genotype, while AC patients had a higher risk of the AA genotype but no significant difference was found, although IL13 patients had a higher risk of the vascular adenine/adenine genotype at a lower risk of the compared to healthy controls Was found a significantly elevated serum periostin in asthmatic patients relative to controls. In patients with IL13 AA and GA genotypes, the incidence was much higher in patients with IL13 AA and GA genotypes compared to those with GG genotype. Conclusion: The serum periostin and serum IL13 levels in allergic patients has been found in Egyptian patients, and a strong positive correlation between serum periostin and serum IL13 has been established, and it positively correlates with IL13 levels, supporting its use as a diagnostic biomarker.
The conjunctiva and the lacrimal soluble molecules' cellular and microbial populations were investigated for the key biomarkers of allergic conjunctivitis for the purpose of this research. A total of 35 healthy people, 28 subjects with seasonal allergic conjunctivitis, and 32 patients with chronic allergic conjunctivitis were recruited to obtain peripheral blood, conjunctival brush cytology, tear fluid, and microbiota samples. An increased number of Th2 and NKT lymphocytes was discovered for perennial allergic conjunctivitis, while CD3+TCRu03b3+ lymphocytes and double negative MAIT cells were decreased. An increase in Th17 and Th22 cell counts was also distinguished by seasonal allergic convulsion, though the Th1 cell number decreased. Among tear fluid, the overwhelming number of pro-inflammatory cytokines in perennial allergies and MMP-9, as well as IgA in seasonal allergies, was elevated.
Source link: https://doi.org/10.3389/fimmu.2022.911022
In the qualitative analysis, five journals describing AC incidence among people with DE and six articles reporting DE incidence among individuals with AC were included in the qualitative analysis. The DE prevalence among people with AC was 0. 9 percent as of 0. 9 percent, which was 6. 2 percent higher than that among people with DE; the AC prevalence among DE residents was 6. 2 percent, which was 38. 0%. According to each study, 47. 2% of patients with AC had comorbid DE and 17. 8% of patients with DE had comorbid AC. In highly vulnerable populations, complimentary screening and treatment for patients with DE and AC may improve long-term outcomes and reduce chronic ocular damage.
Source link: https://doi.org/10.3390/jcm11133643
The stage II trial, which included adult and pediatric asthmatics as well as corresponding controls, involved 306 patients with moderate and severe allergic rhinitis in 306 patients with moderate and severe allergic rhinitis. In stage I, 112 SNPs were tested in the patients' TEK gene in order to look for associations with asthma and allergic conctivitis. The rs3824410 SNP was partially associated with a reduced risk of asthma in the stage I cohort and severe asthma in the asthmatic population in the replication cohort. Due to the limited number of adult patients with conjunctivitis, only children were affected by stage II. In the conventional model, the rs622232 SNP was associated with conjunctivitis in boys, while the rs7034505 showed links to conjunctivitis in girls.
Source link: https://doi.org/10.3389/fgene.2020.00128
In a total of 233 children with seasonal allergic congenital disease, this open-label, multicentre, 4-week trial was conducted to determine the safety and tolerability of twice daily levocabastine eye drops, as well as sodium cromoglycate nasal spray for the relief of concurrent nasal symptoms, if necessary. In patients aged 12 years and 85 percent, respectively, and 30 percent in those u2265-12 years, with corresponding reductions in the total severity of ocular disorders in both patient groups during the 4-week treatment period. The treatment of seasonal allergic congenitis in children appears to be safe and well tolerated by Twice daily levocabastine eye drops.
Source link: https://doi.org/10.1155/S0962935195000792
Group B received 1% topical artemisinin eye drops 4 times per day, and group C received artemisinin at doses of 600 mg/kg orally once per day; group D received topical dexamethasone eye drops 4 times per day; group D received topical dexamethasone eye drops 4 times per day; group D received topical dexamethasone eye drops four times per day; group C received artemisinin eye drops once per day; group B Results: Model group and treatment groups were more prevalent after excitation, allergy symptoms of the model group were more evident than those in the negative control group and treatment groups; allergy symptom score, mast cell degranulation ratios, and the ragweed pollen specific IgE in serum in the topical treatment groups and oral group were all higher than those in the experimental group; but not significantly lower than those in the model group; CONCLUSION: Artemisinin topical and or oral therapy for mice may reduce the signs of pollen allergic conjunctivitis, early-phase reaction of mast cell degranulation ratio, and specific IgE generation for ragweed pollen, indicating that artemisinin has some anti-inflammatory conjunctivitis, pollen allergic conjunctivitis, may be reduced by artemisinin-related pollen allergy in pollen allergic conjunctivitis.
Source link: https://doi.org/10.3980/j.issn.1672-5123.2016.6.07
The detection of novel drug targets, including eosinophils and adhesion molecules, has increased worldwide prevalence of allergic eye pathologies, which is mediated by various adhesion molecules. Multiple mechanisms of action can be helpful in the early and late phases of allergic conjunctivitis by blocking the interaction between u03b21 integrins and vascular cell adhesion molecule -1.
Source link: https://doi.org/10.3389/fphar.2012.00203
RESULTS: The positive results of CIC eosinophil testing in AC patients were also higher than that of the normal control group, with the ability to compare the results between the two groups and analyze the effects of gender, age, and course of disease.
Source link: https://doi.org/10.3980/j.issn.1672-5123.2022.5.38
Ocular allergic disorders are common in ophthalmological clinical practice. Immunological damage is caused by a local Th2 inflammatory microenvironment, as well as changes in circulating cell subsets, with more effector cells and fewer T regulatory cells. We performed an Ag-specific stimulation in peripheral blood mononuclear cells during 72 h of culturing with or without lipopolysaccharide or u03b1-MSH, determining the cell subsets and cytokines induced by the stimulation. We also established u03b1-MSH in tear samples from healthy donors or PAC patients. The number of CD4+TLR4+ cells and cytokines IL-4 and IL-6 were considerably reduced when u03b1-MSH was introduced to the culture, and when u03b1-MSH was added to the mix, the number of CD4+CD25+FoxP3+ cells increased dramatically, while the percentage of CD69+ cells and cytokines IL-4 and IL-6 were significantly reduced, with CD4+TLR4+ cells were also CD25+ cell cytokines &TLR4+FoxP3+ cells were also CD25+FoxP3+FoxP3+FoxP3+FoxP3+FoxP3+FoxP3+FoxP3+FoxP3+FoxP3+FoxP3+FoxG1-TLR4+FoxP3+FoxTLR4+FoxTLR4+TLR4+FoX2+TLR4+TLR4+F In tears, we found an elevated incidence of u03b1-MSH in PAC patients, which was higher than HD. In addition, we established the presence of CD4+TLR4+ cells as an effector cell subtype in ocular allergy.
Source link: https://doi.org/10.3390/ijms21217861
In an integrated review of two Phase III conjunctival allergen challenge trials and a Phase IV environmental allergen study, we investigated the effectiveness of BBOS 1. 5% in relieving nasal symptoms. BBOS 1. 5% had reduced CAC-induced nasal congestion and pruritus at 15 minutes and 8 hours postdosing and rhinorrhea, as well as a non-ocular composite-symptom score at all time points postdosing. BBOS 1. 5 percent reduced sneezing and nasal pruritus over two weeks and a median number of days to improvement in nasal pruritus and overall respiratory symptom score in Phase IV. Conclusion: These exploratory findings indicate that topical ocular BBOS 1. 5% reduced nasal symptoms, supporting its use for treating rhinitis symptoms related to AC.
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions